|
|
|
FDA Home Page | Search FDA Site | A-Z Index | Contact FDA
| Center | Date | Time | Location |
|---|---|---|---|
| CBER | June 9, 2003 | 1:00 p.m. - 3:30 p.m. | National Institutes
of Health |
This meeting will be held by a telephone conference call. Members of the public
attending the meeting may participate during the open session of the meeting
at the specified location.
Agenda:
On June 9, 2003, the committee will receive an update on individual research
programs in the Division of Cellular and Gene Therapies.
Closed Committee Deliberations:
On June 9, 2003, from approximately 3:00 p.m. to 3:30 p.m., the meeting will
be closed to permit discussion where disclosure would constitute a clearly unwarranted
invasion of personal privacy (5 U.S.C. 552b(c)(6)). The committee will discuss
a review of individual research programs in the Center for Biologics Evaluation
and Research.
Procedure:
On June 9, 2003, from 1:00 p.m. to approximately 3:00 p.m. the meeting is open
to the public. Interested persons may present data, information, or views, orally
or in writing, on issues pending before the committee. Written submissions may
be made to the contact person by June 2, 2003. Oral presentations from the public
will be scheduled between approximately 2:00 p.m. and 3:00 p.m. Time allotted
for each presentation may be limited. Those desiring to make formal oral presentations
should notify the contact person before June 2, 2003 and submit a brief statement
of the general nature of the evidence or arguments they wish to present, the
names and addresses of proposed participants, and an indication of the approximate
time requested to make their presentation. Persons attending FDA's advisory
committee meetings are advised that the agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the public at its advisory committee meetings
and will make every effort to accommodate persons with physical disabilities
or special needs. If you require special accommodations due to a disability,
please contact Gail Dapolito at least 7 days in advance of the meeting.
Contact Person:
Gail Dapolito or Rosanna L. Harvey, Center for Biologics Evaluation and Research
(HFM-71), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852,
301-827-0314, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572
in the Washington, DC area), code 12389. Please call the Information Line for
up-to-date information on this meeting.